Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Other Mar 17 | 2020DarioHealth Q4 '19 Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi, Other Mar 17 | 2020Mylan/Aurobindo Invalidates Two Tradjenta Patents; PRV-031 (Teplizumab) Ph3 PROTECT Trial PausedPurchase Blast
$599
Posted in: SGLT2i Mar 12 | 2020Zyquista T1DM CRL stands (Lexicon Q4 '19 Earnings Update); Jardiance CKD Fast Track DesignationPurchase Blast
$599
Posted in: Bolus Insulin, Glucose Monitoring, Other Mar 12 | 2020Lilly to Join New Part D Senior Savings Model for Affordable Insulins; Welldoc Partners With DexcomPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring Mar 10 | 2020Nemaura enters into multiple non-binding agreements for sugarBEAT; Mylan wins over Sanofi in Lantus patent litigationPurchase Blast
$599
Posted in: Other Mar 10 | 2020Thoughts on FDA's New Draft Guidance for T2DM TrialsPurchase Blast
$599
Posted in: SGLT2i Mar 09 | 2020New dapa HF study (DICTATE-AHF) in T2DM patients with acute decompensated heart failurePurchase Blast
$599
Posted in: Other Mar 04 | 2020Voluntis Deprioritizes Diabetes in Favor of OncologyPurchase Blast
$599
Posted in: Insulin Delivery Mar 04 | 2020Thoughts on Tandem Basal IQ iAGC DesignationPurchase Blast
$599
Posted in: Glucose Monitoring Mar 03 | 2020Nemaura Launches sugarBEAT CGM App on Google PlayPurchase Blast
$599
Posted in: GLP-1RA Feb 28 | 2020New Ozempic Switching Study from other GLP-1RA (SUSTAIN SWITCH)Purchase Blast